The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) is a not-for-profit organization, dedicated to a close interaction between clinical scientists dealing with bone, joint and muscle disorder, pharmaceutical industry developing new compounds in this field, regulators responsible for the registration of such drugs and health policy makers, to integrate the management of Osteoporosis and Osteoarthritis within the comprehensive perspective of health resources utilization.

The objective of ESCEO is to provide practitioners with the latest clinical and economic information, allowing them to organize their daily practice, in an evidence-based medicine perspective, with a cost-conscious perception.

"Why Patented Crystalline Glucosamine Sulfate (pCGS) is different from Other Glucosamines in the Treatment of Osteoarthritis (OA) and Should be Recommended as First Line Therapy"
In December 2015, the paper published by Olivier Bruyère, member of the Scientific Advisory Board of ESCEO, in Seminars in Arthritis and Rheumatism (2014) has benefited from a high visibility in the Asian press: a total of 160 media postings in Thailand, China, Russia and in international outlets with a potential audience of almost 80.000.000 visitors a day.
This is a huge opportunity for ESCEO and for our Osteoarthritis Treatment Algorithm to be seen and read all over the world.

Our 2017 congress in Florence, Italy

Our 2018 congress in Krakow, Poland